A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products

Katherine M. Murphy1, Siwon Chung1, Shruti Fogla1, Hana B. Minsky1, Karen Yong Zhu1, Philipp Zerbe1

1Department of Plant Biology, University of California Davis

Introduction

Diterpenoids comprise a chemically diverse group of more than 12,000 predominantly polycyclic 20-carbon natural products that play critical roles in many organisms1. Fungi and plants produce the largest diversity of diterpenoids, but bacteria have also been shown to form bioactive diterpenoids (see reviews2,3,4,5). Rooted in their vast structural diversity, diterpenoids serve a multitude of biological functions. A few diterpenoids, such as gibberellin growth hormones, have essential functions in developmental processes6. However, the majority of diterpenoids serve as mediators of chemical defense and interorganismal interactions. Among these, diterpene resin acids in the pest and pathogen defense of coniferous trees and species-specific blends of antimicrobial diterpenoids in major food crops such as maize (Zea mays) and rice (Oryza sativa) have been most extensively studied7,8,9. These bioactivities provide a rich chemical repository for commercial applications, and select diterpenoids are used as important pharmaceuticals, food additives, adhesives, and other bioproducts of everyday modern life6,9,10. To advance research on the natural diversity and biological functions of diterpenoids and ultimately promote broader commercial applications, tools for the cost-efficient preparation of pure compounds are required. Large-scale isolation from plant material has been established for a few diterpenoid bioproducts, such as diterpene resin acids that are produced as a byproduct of the pulp and paper industry9. However, accumulation of diterpenoids in only specific tissues and under tight regulation by environmental stimuli often limits isolation of sufficient product amounts from the natural producer2. In addition, the structural complexity of diterpenoids hampers their production through chemical synthesis, although such approaches have been successful in several cases11,12. With the availability of advanced genomic and biochemical technologies, enzymatic production platforms have gained increasing attention for producing a range of diterpenoid compounds (see reviews13,14,15,16,17,18).

All terpenoids, including diterpenoids, are derived from two isomeric isoprenoid precursors, isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP)19 that, in turn, are formed through the mevalonate (MVA) or the methyerythritol-5-phosphate (MEP) pathway. Terpenoid biosynthesis proceeds through the MEP pathway in bacteria and the MVA pathway in fungi, whereas plants possess a cytosolic MVA and a plastidial MEP pathway, with the latter being the primary route toward diterpenoid formation20. Condensation of IPP and DMAPP by prenyl transferases yields the central 20-carbon precursor to all diterpenoids, geranylgeranyl diphosphate (GGPP)21. Downstream of GGPP formation, two enzyme families, terpene synthases (TPSs) and cytochrome P450 monoxygenases (P450s) largely control the formation of the vast chemical diversity of terpene metabolism5,22. Diterpene synthases (dTTPSs) catalyze the committed carbocation-driven cyclization and rearrangement of GGPP to form various stereospecific bi-, poly-, or macro-cyclic diterpene scaffolds23,24. Oxygenation and further functional decoration of these scaffolds is then facilitated by P450 enzymes and select other enzyme families25,26. TPSs and P450s commonly exist as
species-specific, multi-gene families that can form modular biosynthetic networks, where combining different enzyme modules along a common blueprint enables the formation of a broad range of compounds. The rapid discovery of functionally distinct enzymes operating in modular terpenoid pathways in recent years has provided expanding opportunities for their use as a versatile parts list for metabolic engineering of partial or complete pathways in both microbial and plant-based production platforms. For example, yeast (Saccharomyces cerevisiae) has been applied successfully to engineer multi-enzyme pathways for the manufacture of terpenoid bioproducts, such as the antimalarial drug artemisinin, the sesquiterpenoid biofuels bisabolene and farnesene, but also select diterpenoids. Likewise, engineered Escherichia coli platforms for the industrial-scale manufacture have been established for a few diterpenoid metabolites, including the Taxol precursor taxadiene used as an anti-cancer drug and the diterpene alcohol, sclareol, used in the fragrance industry. Advances in genetic engineering and transformation technologies also have made plant host systems increasingly viable for producing plant natural products. In particular, the close tobacco relative, Nicotiana benthamiana, has become a widely used chassis for terpenoid pathway analysis and engineering, due to the ease of Agrobacterium-mediated transformation of multiple gene combinations, efficient biosynthesis of endogenous precursors, and high biomass.

Drawing on these established platforms for terpenoid biosynthesis, we describe here easy-to-use and cost-efficient methods for the enzymatic production of diterpenoids and the purification of single compounds. The presented protocols illustrate how E. coli and N. benthamiana platforms engineered for enhanced diterpenoid precursor biosynthesis can be utilized for the combinatorial expression of different dTPSs and P450 enzymes to generate desired diterpenoid compounds. Application of this protocol to produce and purify structurally different diterpenoids is shown by example of specialized diterpenoids from maize (Zea mays), termed dolabralexins, endogenous biosynthesis of which recruits two dTPS and one P450 enzyme. Purification of different dolabralexins ranging from olefins to oxygenated derivatives is then achieved by combining preparative liquid chromatography with preparative high-pressure liquid chromatography (HPLC). The described protocols are optimized for the production of diterpenoids, but can also be readily adapted for related terpenoid classes, as well as other natural products for which enzyme resources are available. Compounds produced using this approach are suitable for various downstream applications, including but not limited to, structural characterization via nuclear magnetic resonance (NMR) analysis, use as substrates for enzyme functional studies, and a range of bioactivity assays.

### Protocol

**CAUTION:** The protocols described here include the use of hazardous chemicals, sharp objects, electrical devices, hot objects, and other hazards that may result in injury. Appropriate personal protective equipment should be worn, and the appropriate safety procedures, including safety trainings, should be followed.

1. **Preparation of materials and solutions**

1. Prepare and autoclave lysogeny broth medium (LB) for 30 min: Per 1 L of medium, mix 10 g of tryptone, 5 g of bacterial yeast extract, and 10 g of NaCl and dissolve in 1 L of deionized (DI) water.

2. For 1 L co-expression cultures, prepare and autoclave Terrific Broth (TB) medium for 30 min: In a 2.8 L Erlenmeyer flask mix 12 g of tryptone, 24 g of bacterial yeast extract, and 40 mL of 10% (v/v) glycerol and dissolve in 860 mL of DI water. Prepare and autoclave 1.3 L of 10x phosphate buffer [1.3 L of DI water, 30.03 g of monopotassium phosphate (KH₂PO₄), and 163.02 g of dipotassium phosphate (K₂HPO₄)] and add to the above medium.

3. Prepare Super Optimal broth with Catabolite repression (SOC) media.
   1. Prepare and autoclave for 30 min a solution containing 2% (w/v) tryptone, 0.5% (w/v) bacterial yeast extract, 8.5 mM NaCl, and 2.5 mM KCl.
   2. Add sterile MgSO₄ and glucose both with a final concentration of 20 mM. Use 1 M NaOH to adjust to pH 7.0. Store the SOC media at -20 °C.

4. Prepare 1 L of 1 M sodium pyruvate. Autoclave for 15 min and store at 4 °C.

5. Prepare 20 mL of 1 M isopropyl β-D-1-thiogalactopyranoside (IPTG) in sterile DI water. Store 1–2 mL aliquots at -20 °C.

6. Prepare infiltration buffer: 10 mM MES (1.952 g) and 10 mM MgCl₂ (2.033 g) dissolved in 1 L of DI water. Store at 4 °C.

7. Prepare and autoclave LB agar for 30 min: Per 100 mL of DI water, add 1 g of tryptone, 0.5 g of bacterial yeast extract, 1 g of NaCl, and 1.5 g of agar. Once LB agar is cool enough to handle the bottle, add antibiotics as required for the desired plasmid combinations. Pour agar plates using petri dishes and store at 4 °C.

   1. See Table 1 for specifications regarding compound production in E. coli and N. benthamiana, respectively. Wrap plates containing rifampicin in foil to prevent degradation upon storage.
2. Production of diterpenoid metabolites in *E. coli*

NOTE: The protocol described here for producing diterpenoid metabolites in *E. coli* has been adapted from a previously reported enzyme co-expression platform developed by the group of Dr. Reuben J. Peters (Iowa State University, IA, USA).

1. **Transformation of competent cells with plasmid combinations.**
   1. Thaw chemically competent *E. coli* cells on ice (BL21DE3-C41 cells were used in this protocol).
   2. Add 1 µL of a 100 ng/µL solution of each construct used for co-expression to 25 µL of competent cells in a 1.5 mL microtube. Do not vortex or mix by pipetting.
   NOTE: For optimal expression and activity of TPS and P450 enzymes, several sequence modifications need to be considered. For TPS, removal of the N-terminal plastidial transit peptide is often essential. Specifically, plastidial mono- and di-TPS typically require removal of the predicted transit peptide (using common prediction algorithms), whereas cytosolic sesqui-TPS can usually be used as full-length genes. With regards to P450s, codon optimization as well as removal or replacement with the leader sequence MAKKTSSKGK of the N-terminal transmembrane domain has proven effective in many cases. In addition, when co-expressing P450 enzymes a cytochrome P450 reductase (CPR) should be included to ensure sufficient P450 activity.
   3. Incubate the mixture on ice for 30 min. Mix every 10 minutes by gently scraping the tube across a microtube rack.
   4. Pre-incubate SOC media and LB agar plates at 37 °C containing antibiotics as required for the desired combination of constructs.
   NOTE: Each construct to be co-transformed must have a distinct antibiotic resistance, as well as distinct origins of replication to ensure optimal protein expression.
   5. Heat shock the cell mixture at 42 °C for 1 minute, and then incubate on ice for at least 2 min.
   6. Add 200 µL of warm SOC media.
   7. Shake the cell mixture for 1 h at 37 °C and 200 rpm.
   8. Add approximately 10 autoclaved glass beads to the warmed LB agar plate. Add 100 µL of the cell mixture and replace the lid. Shake plate horizontally with the lid on to distribute the cells evenly. Remove the glass beads by tapping them off into a waste container. Alternatively, use other preferred plating methods.
   9. Incubate the LB agar plate at 37 °C overnight with the coated surface face down. The plate with transformed *E. coli* colonies can be used the following day or stored at 4 °C sealed in paraffin film for up to 2 weeks.

2. **Preparation of inoculation cultures**
   1. On the following day, prepare a solution of LB medium with antibiotics required for the transformed plasmid combination using the concentrations provided in Table 1.
   2. In a sterile hood, transfer 5 mL of LB medium to a 15 mL sterile glass test tube with a plastic breathable cap. Prepare one small culture tube for each desired large (1 L) culture.
   3. Select individual *E. coli* colonies from the LB agar plate using a pipette tip. Inoculate each tube of LB with an *E. coli* colony by ejecting one pipette tip containing a selected colony into each tube.
   4. Cap each inoculation culture test tube with a breathable plastic cap. Place the capped *E. coli* small cultures in a 37 °C shaking incubator for 12–24 h.

3. **Preparation and induction of co-expression cultures**
   1. On the following day, add 100 mL of prepared 10x phosphate buffer to 900 mL of prepared TB for a final phosphate buffer concentration of 1x. Add necessary antibiotics with concentrations according to Table 1.
   2. Shake at 140 rpm at 37 °C until warm (approximately 30 min).
   3. Inoculate each flask of media for 1 L cultures with 5 mL of the inoculation culture. Retain the pipette tip used for inoculation culture inoculation in the inoculation culture tube so that, upon extraction with organic solvent in subsequent steps, there are no extracted plastic contaminants.
   4. Incubate with shaking at 200 rpm until the optical density at 600 nm (OD$_{600}$) reaches 0.6, approximately 3 h. To measure the OD$_{600}$ with a spectrophotometer, use a mixture of sterile TB with phosphate buffer as a blank.
   5. At the desired OD$_{600}$, set the incubator settings to 16 °C.
   6. When co-expressing P450s, freshly prepare riboflavin and aminolevulinic acid, which are essential for sufficient P450 co-factor production. For every experiment, make 4 g/L riboflavin and 150 g/L aminolevulinic acid. Keep solution wrapped in foil until use, as riboflavin is light sensitive.
   7. After the incubator has reached 16 °C (approximately 30 min), add 1 ml of 1 M IPTG, 1 mL of 4 g/L riboflavin, and 1 mL of 150 g/L aminolevulinic acid to each culture. For diterpenoid production, 25 mL of 1 M sodium pyruvate should be added to each culture to assure sufficient precursor formation.

### Table 1: Antibiotic concentrations for plasmid co-expression in *E. coli* or *N. benthamiana*.

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Stock (mg/mL)</th>
<th>Solvent</th>
<th>Working concentration (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 plasmid</td>
</tr>
<tr>
<td>Carbenicillin</td>
<td>50</td>
<td>H$_2$O</td>
<td>50</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>30</td>
<td>EtOH</td>
<td>30</td>
</tr>
<tr>
<td>Kanamycin</td>
<td>50</td>
<td>H$_2$O</td>
<td>50</td>
</tr>
<tr>
<td>Spectinomycin</td>
<td>30</td>
<td>H$_2$O</td>
<td>30</td>
</tr>
<tr>
<td>Gentamycin</td>
<td>50</td>
<td>H$_2$O</td>
<td>30</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>10</td>
<td>MeOH</td>
<td>10</td>
</tr>
</tbody>
</table>

*E. coli* or *N. benthamiana*.
NOTE: All constructs used in this assay were under the same IPTG-inducible promoter. Different promoters can be used as desired.

8. Incubate at 16 °C and 140 rpm for 72 h. Add 25 mL of sodium pyruvate each subsequent day after induction if producing diterpenoids. Immediately use cultures are immediately used for separatory funnel extraction of metabolites; do not harvest or store cultures.

3. Separation and purification of metabolites

1. Separatory funnel extraction of metabolites

   NOTE: It is important to use only glassware and glass pipettes when using organic solvents to prevent plasticizer contaminations.

   1. In a fume hood, secure the separatory funnel onto a ring stand. Place a waste beaker underneath the separatory funnel.
   2. Pour 500 mL of 50/50 (v/v) ethyl acetate/hexanes into the separatory funnel.
   
   NOTE: Solvent mixture should be adjusted based on the solubility and polarity of the targeted metabolites. Water-miscible solvents should be avoided to ensure suitable phase separation.
   3. Add 500 mL of the *E. coli* culture to the separatory funnel and place on the glass stopper.
   4. Shake the funnel to mix the culture with the extraction solvent, approximately 5–10x. Frequently de-gas the funnel by opening the spigot while the funnel is held upside down and pointed into the fume hood to release pressure. Repeat the shaking and de-gas procedure 2x.
   5. Place the funnel upright in the ring stand and wait until the solvent layer (top) has separated from the aqueous (culture) layer (bottom), approximately 1 min.

   NOTE: When a large amount of bubbles is observed in the interphase, addition of a small volume of 5–10 mL EIOH can be added to improve phase separation.
   6. Remove the stopper. Drain the *E. coli* layer into a waste beaker, retaining the solvent layer in the funnel.
   7. Repeat the procedure using the remaining 500 mL of *E. coli* culture and the same 500 mL solvent used for the first extraction.
   8. Drain the solvent containing the extracted metabolites into a clean flask. Avoid contamination with *E. coli* culture.

2. Rotary Evaporation Concentration

   1. Prepare the rotary evaporation (rotovap) equipment: fill the water bath and set the temperature to 25 °C. For heat sensitive compounds, use a lower temperature setting or add ice to the water bath. Fill the condensing chamber with dry ice and set the rotating speed to 60–80 rpm.
   2. Add approximately 700 mL of extracted metabolites to a 1 L evaporating flask, attach to the rotovap, and lower into the water bath. Turn the water bath heater on and set to 25 °C.
   3. Start rotation of the evaporating flask, turn on the vacuum system, and gradually increase the suction to avoid rapid boiling of the metabolite solution into the waste flask. Evaporated solvent should begin condensing and dripping into the condensate-collecting (waste) flask.
   4. When only a few mL of the metabolite solution remains in the evaporating flask, stop rotations and turn off the vacuum system. Raise the evaporating flask and depressurize by closing the vacuum line. Retain concentrated metabolite solution remaining in the evaporating flask. Dispose of the waste in the waste flask.
   5. Continue rotary evaporation by adding up to 700 mL of additional extracted metabolite solution to the evaporating flask. Repeat process until all of the extracted metabolite solution has been concentrated.
   6. Remove the concentrated metabolites from the evaporating flask by transferring with a glass pipette to new test tube. Rinse evaporating flask with 5 mL of 50/50 (v/v) ethyl acetate/hexanes or desired solvent mixture two times, transferring the rinsing solution to the test tube.
   7. Store concentrated metabolites at -20 °C or -80 °C (depending on product stability) until further use.

3. Silica Column Purification

   1. Prepare glassware by rinsing a 1 L beaker, glass funnel, 50 mL test tubes, and 3.2 L chromatography column (equipped with a glass frit) once with hexane and once with ethyl acetate. Label the 50 mL test tubes, which will be used to collect fractions.
   2. Add 2 L of silica gel (230–400 mesh, grade 60) to a 3.2 L chromatography column with a 2 L reservoir capacity and a fritted disk, then load sand to form a 5 cm layer at the top of the column.
   3. Prepare the column for chromatography by flushing it thoroughly with 2 L of hexane. At all times, there should be a thin (~0.5 cm) layer of the solvent liquid above the sand layer of the column to ensure the column does not dry out or acquire air pockets. A glass inlet adaptor connected to an air hose can be used to gently increase the flow rate through the column rather than gravity alone.
   4. Load the concentrated metabolite extract (see section 3.2) onto the column. Rinse the bottle that contained the sample 3x with hexane and add to the column to ensure all of the sample has been transferred.
   5. Using the following gradient, load 100 mL at a time and collect 50 mL fractions in labeled test tubes: 100% hexanes 3x, 10% (v/v) ethyl acetate in hexanes 3x, 12.5% (v/v) ethyl acetate in hexanes 3x, 15% (v/v) ethyl acetate in hexanes 3x, 20% (v/v) ethyl acetate in hexanes 3x, 40% (v/v) ethyl acetate in hexanes 3x, 60% (v/v) ethyl acetate in hexanes 3x, and 100% ethyl acetate 4x.

   NOTE: Gradient should be adjusted based on compound size and polarities and desired separation.
   6. Using a glass pipette, transfer 1 mL from each fraction into a labeled GC vial. Analyze each sample via GC-MS to determine which fractions contain the desired metabolites and their level of purity.

   NOTE: The GC-MS method suitable for the metabolites produced in this method has been described in Mafu et al. 2018. In brief, all analyses were performed on an GC with an XL MS detector using an HP-5MS column (see Table of Materials), a sample volume of 1 µL, and oven temperature ramp from 50 °C to 300 °C at 20 °C min⁻¹.
   7. After determining which fractions contain the compound(s) of interest, combine all fractions that contain the same compound. Properly dispose of fractions that do not contain any compounds into a waste container. Repeat the rotary evaporation procedure if necessary to concentrate the purified metabolites.
   8. If additional purification is necessary, use (semi)preparative HPLC to improve product purity. HPLC protocols should be adapted based on individual equipment specifications and compounds of interest.
4. Production of diterpenoid metabolites using *N. benthamiana*

NOTE: The protocol described here for producing diterpenoid metabolites in *N. benthamiana* has been adapted from previously reported studies[^35,36,40,41]. The below protocol is specific to syringe-infiltration of *N. benthamiana* leaves. Other infiltration methods, such as vacuum infiltration are equally suitable. Binary T-DNA vector systems, such as pCAMBIA130035Su (pLIFE33) or pEAQ-HT[^10,41,42], that enable propagation in *E. coli* and *A. tumefaciens* and gene expression in plant hosts are suitable for this protocol.

1. **Planting ** *Nicotiana benthamiana*
   1. Fill one 750 mL pot with potting soil and water the pot. Add ~20 tobacco seed and gently tap with finger so that they are in the soil. Do not cover with soil.
   2. Prune 4-week-old *N. benthamiana* plants 2 days before infiltration by removing lower leaves. Leave 4 uppermost leaves. Water the plants every other day by placing water in the tray the pots are in (also called “bottom watering”). Every fourth watering, include generic fertilizer in the water according to package instructions.
   3. After 1 week, fill ~20 pots with potting soil and water the pots. Using forceps, grasp a tobacco seedling by the stem and gently remove from the source pot, placing one seedling in each new pot and carefully burring the roots. Do not damage the leaves or roots.
   4. Water the plants every other day by placing water in the tray the pots are in (also called “bottom watering”). Every fourth watering, include generic fertilizer in the water according to package instructions.

2. **Freeze-thaw transformation of Agrobacterium tumefaciens** strain GV3101 competent cells
   1. Thaw *Agrobacterium tumefaciens* strain GV3101 (or other preferred strain) competent cells on ice (~1 h). Pre-chill 0.2 mL microcentrifuge tubes on ice. Warm SOC media at 28 °C.
   2. Gently mix cells with the pipet tip (do NOT pipet up and down) and aliquot 15 µL of cells for each transformation into the chilled 1.5 mL microtubes.
   3. Add 1-5 µL (~400 ng) of DNA to each tube of competent cells and mix gently by scraping tube along a tube rack.
   4. Plate 50 µL of transformed cells onto LB agar plates containing the necessary antibiotics described in Table 1 using sterile glass beads, as described in step 2.1.8.
   5. Incubate plates inverted at 28–30 °C for 48 h. Growth within the 4th day of incubation may be a sign of contamination. Transformed *A. tumefaciens* plates can be used following the 2nd incubation or stored at 4 °C sealed in paraffin film for up to 2 weeks.

3. **Agrobacterium-mediated transient enzyme co-expression in Nicotiana benthamiana**
   1. Prune 4-week-old *Nicotiana benthamiana* plants 2 days before infiltration by removing lower leaves. Leave 4 uppermost leaves. Water the plants. Do not water the plants 24 h before infiltration in order to allow for open stomata and easier infiltration.
   2. Add 10 mL of LB with working concentrations of the appropriate antibiotics for chosen constructs and *Agrobacterium* strain (described in Table 1) to a 50 mL sterile glass test tube with a foil lid.
   3. Inoculate using a pipette tip to swab a single colony of transformed *Agrobacterium* and eject the tip into the LB media. Each *Agrobacterium* transformant should have at least 2 small cultures.
   4. Incubate overnight at 28 °C and 220 rpm.
   5. Measure optical density at 600 nm (OD_{600}) of the overnight cultures using a spectrophotometer. Dilute the overnight cultures to an OD_{600} of 1.
   6. Distribute 10 mL of diluted overnight culture into 50 mL conical tubes.
   7. Harvest the bacteria by centrifugation at 3500 rpm for 15 min at room temp. Pour off and discard the supernatant.
   8. Re-suspend the cultures in 10 mL infiltration buffer by gently shaking the tube and rolling on a tube rack. The OD_{600} should equal 1 for each construct.
   9. Generate the combinations desired for infiltrations by combining equal volumes of each transformed cell line. The OD_{600} should equal 1 for each infiltration. Estimate 5 mL of infiltration solution per leaf, 2 leaves per plant.
   10. Attach tubes horizontally to a rocker and rock gently for 2 h at room temperature.
   11. Infiltrate ~2 leaves per *N. benthamiana* plant using approximately 5 mL of infiltration mixture per leaf. Infiltrate healthy leaves with a needleless syringe on the underside of the leaves while exerting a counter-pressure with a finger on the top side of the leaf to ensure infiltration solution suffuses the leaf tissue.
   12. Mark all infiltrated leaves with a black marker or other indicator. Place infiltrated plants in the growth chamber for 5 days. Keep plants well-watered.
4. Metabolite extraction and purification from transformed Nicotiana benthamiana

1. Harvest infiltrated leaves from plants by clipping them from the plant. Add ~100 mL of liquid nitrogen and a single leaf to a mortar, then grind using a mortar and pestle or tissue mill until obtaining a fine powder.

2. Add powdered tissue to a GC-MS vial to the 500 μL demarcation. Add 1.5 mL of 50/50 (v/v) ethyl acetate/hexane or desired solvent mixture to the vial and cap tightly.

   1. For extractions that have been tested to provide the desired products, pool ground tissue into a larger flask or test tube, then add ~2x the amount of solvent than tissue volume and shake overnight. Proceed to step 4.4.5 for purification.

3. Place all vials in a microtube rack and tape down tightly to secure. Extract under vigorous shaking overnight at room temperature.

4. Transfer 400 μL of extract and 600 μL of hexane into a fresh GC-MS vial. Do not aliquot any leaf tissue. Analyze samples using GC-MS using the method described in step 3.3.6.1.

5. Analysis via GC-MS for presence of desired metabolites, pool leaf extracts together and proceed through rotary evaporation, silica column chromatography, and HPLC to obtain pure compounds as described in sections 3.2 and 3.3.

Representative Results

Schematic workflow for diterpenoid production using E. coli

Figure 1 illustrates the described workflow for diterpenoid production. The protocol outlined here has been adapted from a previously described 0.5 μL platform for diterpenoid biosynthesis13,32 for use of larger-volume cultures and purification of desired diterpenoid products via silica chromatography. To demonstrate the use of this protocol, we used a recently identified dolabralexin pathway from maize that comprises two dTPSs, ZmAN2 (Zm00001d029648) and ZmKL4 (Zm00001d032858), a multi-functional P450 (CYP71Z18, Zm00001d014134), and a cytochrome P450 reductase (ZmCPR2, Zm00001d026483) (Figure 2). In brief, E. coli BL21DE3-C41 competent cells were pre-transformed with the pCDFDuet:IRS and pACYC-Duet:GGPPS/ZmAN2 plasmids13,32. The pCDFDuet:IRS plasmid contains key enzymes for diterpenoid precursor production, including 1-deoxy-D-xylulose-5-phosphate synthase (dxs), 1-deoxy-D-xylulose-5-phosphate reductase (dxr), and isopentenyl diphosphate isomerase (idi), and was shown to increase diterpenoid formation in E. coli13. The pACYC-Duet:GGPPS/ZmAN2 plasmid contains the maize ent-copalyl diphosphate synthase ZmAN2 and a GGPP synthase from Abies grandis. Enzymes catalyzing the committed reactions in dolabralexin biosynthesis were then co-transformed as plasmids pET28b:ZmKL4 and pETDUET:ZmCPR2/ZmCYP71Z18. For details on sequences and plasmid constructs see Mafu et al. 201833.

A GC-MS chromatogram of the extracted enzyme products is shown in Figure 3A. Illustrating the formation of three dolabralexin compounds, namely dolabradiene (1.2 ± 0.25 mg/L culture), epoxydolabrene (0.65 ± 0.2 mg/L culture), and epoxydolabranol (11.4 ± 1.1 mg/L culture) as quantified based on a standard curve using the diterpenoid scolareol. Scolareol was used as a reference standard, due to its similar structure and chemical properties as compared to dolabralexins. Typically observed minor byproducts include chloramphenicol, the indole derivatives oxindole and indole-5-aldehyde, and the precursor geranylgeranyl diphosphate (GGPP) (Figure 3). Indole commonly represents the primary byproduct, but is not shown here, due to its retention time shorter than the set solvent delay of 7 min to preserve the integrity of the GC-MS instrument.

Schematic workflow of diterpenoid production using N. benthamiana

Figure 4 depicts an overview of the expression of the dolabralexin pathway in N. benthamiana. For the products described here, the following constructs were separated into A. tumefaciens (pLife33:p19) strain GV3101: pLife33:p19 (expressing the p19 gene silencing suppressor protein), pLife33:ZmCYP71Z18, pLife33:ZmAN2, pLife33:ZmKL4. Full-length native sequences of the maize dolabralexin pathway genes were used in the binary T-DNA vector pLife3331 with kanamycin resistance for propagation in E. coli and pLife33. Co-expression of upstream terpenoid pathway genes is optional, since the precursor geranylgeranyl diphosphate is endogenously formed in N. benthamiana. However, several studies have successfully employed such approaches to increase diterpenoid formation in N. benthamiana18,26,41. As illustrated in Figure 3, co-expression successfully produced dolabradiene and 15,16-epoxydolabrene. Unlike enzyme co-expression in E. coli, 15,16-epoxydolabranol was not detected in metabolite extracts.

Presence of 15,16-epoxydolabrene in leaf extracts demonstrated the activity of CYP71Z18 in N. benthamiana. As 15,16-epoxydolabranol was shown to be stable after extraction from microbial cultures (Figure 3) as well as after isolation from maize root tissues in previous studies39, it appears plausible that the hydroxylated product is glycosylated by endogenous glycosyltransferases and subsequently sequestered in the vacuole, rendering it inaccessible to extraction with the organic solvent mixtures used here for extraction26,43,44,45,46. Similar undesired product modifications in the context of pathway engineering in N. benthamiana have been reported in previous studies47. As shown for co-expression in E. coli, transient expression in N. benthamiana results in the extraction of several byproducts, including linear alkanes of different chain length as based on comparison to reference mass spectra databases. Compound titers extracted from leaf material were found to be on average 2.4 ±/− 0.5 mg dolabradiene and 0.8 ±/− 0.3 mg 15,16-epoxydolabrene per g dry leaf tissue. These titers cannot be compared directly to the E. coli co-expression system given the different experimental set ups.

Diterpenoid purification

Diterpenoid purification was achieved using silica column chromatography and subsequent semi-preparative HPLC. Metabolite extracts from 12 L of pooled E. coli cultures were purified using silica column chromatography to separate the three focal dolabralexin compounds (Figure 3A). Silica chromatography is ideal for achieving high purity of the target compounds, since it enables simple separation of diterpene olefins and oxygenated derivatives, and readily removes the major contaminant, oxindole, which is retained on the silica matrix (Figure 3A).
Figure 1: Workflow for diterpenoid production in *E. coli* and metabolite purification from liquid bacterial cultures. Dashed boxes depict optional steps where additional purification is required. (A) Representative image of extracted *E. coli* culture using a separatory funnel. (B) Representative image of metabolite extract purification using silica chromatography. Please click here to view a larger version of this figure.
Figure 2: Dolabralexin biosynthetic pathway and gene constructs used in this study. Please click here to view a larger version of this figure.
Figure 3: GC-MS results. Shown are representative GC-MS chromatograms of purified diterpenoid products obtained using enzyme co-expression assays in (A) E. coli and (B) N. benthamiana. Product identifications are based on comparisons to authentic standards and reference mass spectra of the National Institute of Standards and Technology (NIST) mass spectral library. 1, oxindole; 2, indole-5-aldehyde; 3, Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)-; 4, 6-O-Acetyl-1-[[4-bromophenyl]thio]-a-d-glucoside S,S-dioxide; 5, dolabradiene; 6, 15,16-epoxydolabrene; 7, Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)-; 8, 15,16-epoxydolabranol; 9 and 12, unknown; 10, chloramphenicol; 11, 3,7,11,15-tetramethyl-2-hexadecen-1-ol; 13-16, alkanes. Please click here to view a larger version of this figure.
Discussion

Broader investigation and application of diterpenoid natural products necessitates simple, inexpensive protocols to synthesize and purify sufficient quantities of desired compounds. The rapid increase in the number of available diterpenoid-metabolic enzymes from a broad range of species now provides an expansive inventory for the enzymatic production of diterpenoids using microbial and plant-based host systems. In addition, the modular architecture of many diterpenoid pathways enables the use of enzymes from the same or different species in ‘plug & play’ combinatorial engineering approaches to generate an array of natural and new nature-like diterpenoid natural products.

E. coli is a preferred microbial host for natural product biosynthesis due to its robustness, ease of scalability, limited chemical complexity for reduced byproduct contamination, and the wealth of available tools for DNA assembly and expression optimization. In our experience, the platform described here is well-suited for producing product yields of up to several hundred mg of diterpene olefins and alcohols, which is suitable for many downstream applications including those proposed here. While not meeting industrial scale, the production platform described here can serve as a foundation for further pathway, host, and fermentation optimization as has been successfully demonstrated for related diterpenoids such as taxadiene and sclareol. Over-expression of rate-limiting MVA or MEP pathway genes has been successfully established to overcome yield-limiting factors for diterpenoid biosynthesis, such as insufficient precursor supply and precursor flux into competing pathways. Although proven successful in several studies, poor expression and catalytic activity of terpenoid-metabolic eukaryotic P450s and other membrane-bound enzymes in E. coli is a likely limiting factor. Use of codon-optimized sequences and protein modifications, such as removal of the endoplasmic reticulum signal peptide or introduction of a plastidial signal peptide, have proven useful to increase soluble P450 expression.

With the broader availability of genetics and genomics resources, plant host systems also become increasingly suitable for the manufacture of natural products. Advantages include the ability of plants to produce the required natural precursors powered by photosynthesis, thus enabling product formation without the need to supplement precursor molecules. N. benthamiana is already widely used for in vivo functional characterization and combinatorial expression of terpenoid and other natural product pathways. Notable advantages of using N. benthamiana as a host system include the endogenous production of diterpenoid precursors, use of native gene sequences, simplified expression of eukaryotic P450s, ease of combinatorial gene transformation (as separate antibiotics are not required for transient co-transformation), and simple extraction of target products from leaf material. Where needed, diterpenoid production can be enhanced through co-expression of key MEP pathway genes to increase precursor supply. Constraints for scalable diterpenoid production in N. benthamiana are more complex as compared to liquid microbial cultures due to the need for generating sufficient plant biomass, more labor-intensive product purification from chemically complex plant tissue, and possible undesired metabolization of target products through, for example, oxidation,
glycosylation or dephosphorylation by endogenous enzymes\textsuperscript{36,43,44,45,46,47}. However, this procedure can be scaled up to mg product quantities by increasing the number of plants used for agroinfiltration\textsuperscript{36}.

The product extraction and purification protocols described here are compatible with \textit{E. coli} and \textit{N. benthamiana}, as well as \textit{S. cerevisiae} and other plant or microbial host systems, and provide a cost-efficient approach that is easy to set up in both biology and chemistry laboratories and does not require expensive purification equipment. Metabolite extraction using a separatory funnel is well-suited for efficient extraction and phase separation prior to chromatographic purification. Funnel sizes can be readily adjusted to allow for larger culture volumes and reduce experimental time needed to extract from large cultures. We found the use of a hexane/ethyl acetate gradient to be ideal for extracting diterpenoids of different polarity as demonstrated here for the group of dolabraxelins that comprise both hydrocarbon and oxygenated compounds (Figure 3). Depending on the properties of target products, other solvent mixtures may be advantageous. However, solvents must not be miscible with water to ensure successful extraction and phase separation using the separatory funnel technique. In addition, product loss through evaporation must be taken into account when using this approach for producing volatile organic compounds (VOCs), such as lower molecular weight mono- and sesqui-terpenoids and other VOCs. Chromatographic separation of diterpenoids of different levels of oxygenation using a larger-scale (~2 L) silica column has been advantageous in our experience, since it provides improved product separation and minimizes the need for iterative purification steps when using smaller column volumes. Column volumes and matrices can be adjusted as needed for the desired culture volume and the type of natural product. The purity of target products that can be achieved using this protocol is suitable for many downstream applications, such as bioactivity assays or for use in enzyme activity analyses. However, where higher purity levels are required, such as structural analyses via NMR, product purity can be efficiently enhanced by additional purification using (semi)-preparative HPLC.

This protocol described here has been optimized for the production of diterpenoid natural products, but can also be readily customized to related mono-, sesqui- and tri-terpenoids, as well as other natural product classes simply by generating the desired enzyme modules for combinatorial expression\textsuperscript{13,57}. However, modifications of the procedures for product extraction and purification must be taken into consideration for compounds with higher volatility, such as mono- and sesqui-terpenoids, or higher polarity and functional modification as exemplified by glycosylation of many triterpenoids, phenylpropanoids, and other natural product classes.

Although industrial-scale platforms for the manufacture of natural products are available, the protocols described here offer an inexpensive, customizable tool that can be readily set up in most laboratories. As demonstrated by the production of maize dolabraxelins here and elsewhere\textsuperscript{36}, the product quantities and purity that can be achieved using this approach are typically sufficient to facilitate various downstream analysis and uses, including, but not limited to, various bioactivity studies, analysis of interactions between organisms, as well as for use as enzyme substrates or as starting material for semi-synthesis approaches.

Disclosures

The authors declare they have no competing financial interests.

Acknowledgments

We gratefully acknowledge Dr. Reuben Peters (Iowa State University, USA) for providing the pIRS and pGGxZmAN2 constructs. Financial support for this work by the NSF Plant-Biotic Interactions Program (grant# 1758976 to P.Z.), the DOE Early Career Research Program (grant# DE-SC0019178 to P.Z.), the DOE Joint Genome Institute Community Science Program (grant# CSP2568 to P.Z.), the NSF Graduate Research Fellowship Program (to K.M.M.), and a UC Davis Dean’s Mentorship Award Fellowship (to K.M.M.) are gratefully acknowledged.

The authors declare they have no competing financial interests.

References

1. Peters, R. J. Two rings in them all: the labdane-related diterpenoids. \textit{Natural Product Reports.} \textbf{27} (11), 1521-1530 (2010).
3. Toyomasu, T. Recent advances regarding diterpene cyclase genes in higher plants and fungi. \textit{Bioscience, Biotechnology, and Biochemistry.} \textbf{72} (5), 1168-1175 (2008).
44. Wang, B. et al. Transient production of artemisinin in Nicotiana benthamiana is boosted by a specific lipid transfer protein from A. annua. Metabolic Engineering. 38, 159-169 (2016).
57. Moses, T. et al. OSC2 and CYP716A14v2 catalyze the biosynthesis of triterpenoids for the cuticle of aerial organs of Artemisia annua. The Plant Cell. 27 (1), 286-301 (2015).